Literature DB >> 24015116

Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Jared Minkel, Andrew D Krystal.   

Abstract

A number of medications are available for treating patients with insomnia. These medications include agents approved as insomnia therapies by the U.S. Food and Drug Administration (FDA), agents approved by the FDA for another condition that are used "off-label" to treat insomnia, and agents available "over-the-counter" that are taken by individuals with insomnia. These agents differ in their properties, their safety and efficacy when used for different insomnia patient subtypes, and the available data on their efficacy and safety in these subtypes. As a result, optimizing the medication treatment of insomnia for a given patient requires that the clinician select an agent for use which has characteristics that make it most likely to effectively and safely address the type of sleep difficulty experienced by that individual. This article is intended to assist clinicians and researchers in carrying out this optimization. It begins by reviewing the basic characteristics of the medications used to treat insomnia. This is followed by a review of the fundamental ways that individuals with insomnia may differ and affect the choice of medication therapy. This review includes discussions that illustrate how to best choose a medication based on the characteristics of the available medications, the key differences among insomnia patients, and the available research literature. Lastly, we discuss future directions for the optimizing pharmacologic management of insomnia. It is hoped that the treatment tailoring methods discussed herein serve as a means of improving the clinical management of insomnia and, thus, improve the lives of the many patients who suffer from this common and impairing condition.

Entities:  

Keywords:  Insomnia; Pharmacotherapy

Year:  2013        PMID: 24015116      PMCID: PMC3763861          DOI: 10.1016/j.jsmc.2013.06.002

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN: 1556-407X


  115 in total

1.  Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression.

Authors:  P D Londborg; W T Smith; V Glaudin; J R Painter
Journal:  J Affect Disord       Date:  2000-12       Impact factor: 4.839

Review 2.  Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications.

Authors:  Andrew D Krystal; Elliott Richelson; Thomas Roth
Journal:  Sleep Med Rev       Date:  2013-01-26       Impact factor: 11.609

3.  Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study.

Authors:  C Andrade; B S Srihari; K P Reddy; L Chandramma
Journal:  J Clin Psychiatry       Date:  2001-01       Impact factor: 4.384

4.  Effects of doxylamine and acetaminophen on postoperative sleep.

Authors:  G M Smith; P H Smith
Journal:  Clin Pharmacol Ther       Date:  1985-05       Impact factor: 6.875

5.  Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.

Authors:  Andrew D Krystal; Alan Lankford; H Heith Durrence; Elizabeth Ludington; Philip Jochelson; Roberta Rogowski; Thomas Roth
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

Review 6.  Therapeutic responses to tricyclic antidepressants and related drugs in non-affective disorder patient populations.

Authors:  D L Murphy; L J Siever; T R Insel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1985       Impact factor: 5.067

7.  Use of slow-release melatonin in treatment-resistant depression.

Authors:  E J Dalton; D Rotondi; R D Levitan; S H Kennedy; G M Brown
Journal:  J Psychiatry Neurosci       Date:  2000-01       Impact factor: 6.186

8.  Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study.

Authors:  D Riemann; U Voderholzer; S Cohrs; A Rodenbeck; G Hajak; E Rüther; M H Wiegand; G Laakmann; T Baghai; W Fischer; M Hoffmann; F Hohagen; G Mayer; M Berger
Journal:  Pharmacopsychiatry       Date:  2002-09       Impact factor: 5.788

9.  Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.

Authors:  Thomas Roth; Andrew Krystal; Frank J Steinberg; Nikhilesh N Singh; Margaret Moline
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

10.  Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics?

Authors:  F Hohagen; R F Montero; E Weiss; S Lis; E Schönbrunn; H Dressing; D Riemann; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

View more
  7 in total

1.  Evidence for the etiopathogenesis of insomnia and its psychiatric risk.

Authors:  Julio Fernandez-Mendoza
Journal:  Sleep       Date:  2014-08-01       Impact factor: 5.849

2.  Decline in cardiorespiratory fitness and odds of incident sleep complaints.

Authors:  Rodney K Dishman; Xuemei Sui; Timothy S Church; Christopher E Kline; Shawn D Youngstedt; Steven N Blair
Journal:  Med Sci Sports Exerc       Date:  2015-05       Impact factor: 5.411

Review 3.  New Developments in Insomnia Medications of Relevance to Mental Health Disorders.

Authors:  Andrew D Krystal
Journal:  Psychiatr Clin North Am       Date:  2015-09-11

4.  Suvorexant: The first orexin receptor antagonist to treat insomnia.

Authors:  Ashok K Dubey; Shailendra S Handu; Pramod K Mediratta
Journal:  J Pharmacol Pharmacother       Date:  2015 Apr-Jun

Review 5.  Selecting a pharmacotherapy regimen for patients with chronic insomnia.

Authors:  Amanda B Hassinger; Nikolas Bletnisky; Rizwan Dudekula; Ali A El-Solh
Journal:  Expert Opin Pharmacother       Date:  2020-03-23       Impact factor: 3.889

6.  Shared correlates of prescription drug misuse and severe suicide ideation among clinical patients at risk for suicide.

Authors:  Joseph E Logan; Allison M Ertl; Whitney L Rostad; Jeffrey H Herbst; E Ashby Plant
Journal:  Suicide Life Threat Behav       Date:  2020-08-28

Review 7.  Prevalence of Sleep Disturbances in Pediatric Cancer Patients and Their Diagnosis and Management.

Authors:  Irtiza N Sheikh; Michael Roth; Peter L Stavinoha
Journal:  Children (Basel)       Date:  2021-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.